Novo Nordisk shifts to commercial fixes

Novo Nordisk is trying to fix a drug launch problem with consumer-brand talent, not a new obesity medicine. (ft.com) At its March 26, 2026 annual meeting, Novo named Mars chief executive Poul Weihrauch a board observer and added Helena Saxon, an H&M board member, alongside pharma executives Jan van de Winkel and Ramona Sequeira. Reuters reported the moves were aimed at strengthening Novo’s position in the U.S. obesity market. (usnews.com) Chair Lars Rebien Sørensen said Novo wants to treat people “more as customers than as patients” as it studies where people seek treatment, how they buy and which access routes they prefer. Novo has been pushing telehealth, retail partnerships and direct-to-consumer channels in the United States. (usnews.com) The urgency showed up in Novo’s February 4, 2026 outlook. The company said 2025 sales rose 10% at constant exchange rates, but it expects 2026 sales and operating profit to fall 5% to 13%. (novonordisk.com; fiercepharma.com) Novo tied that weaker forecast to lower U.S. prices, intensifying competition and its “Most Favored Nation” pricing deal with the Trump administration. That November 6, 2025 agreement cut prices for glucagon-like peptide-1 drugs in Medicare and Medicaid and added discounted direct sales through a federal website. (fiercepharma.com; cnbc.com) Glucagon-like peptide-1 drugs mimic a gut hormone that helps control blood sugar and appetite. Novo sells semaglutide under the diabetes brand Ozempic and the obesity brand Wegovy, and those two products brought in about 127 billion Danish kroner and 79.1 billion Danish kroner, respectively, in 2025. (novonordisk.com; fiercepharma.com) Novo is also changing how it sells the franchise. It launched the first oral glucagon-like peptide-1 treatment for obesity in the United States on January 5, 2026, and Reuters said the company chose multiple cash-pay channels instead of relying only on traditional insurance coverage. (cnbc.com; usnews.com) Chief executive Maziar Mike Doustdar said in early February that more than 170,000 people had started the Wegovy pill in about four weeks. Novo presented that uptake as evidence that a broader obesity market could be built if the company got pricing and access right. (fiercepharma.com) The leadership reset is recent. Novo said Mike Doustdar succeeded Lars Fruergaard Jørgensen as president and chief executive on August 7, 2025, and the company later reworked its board as sales growth slowed in the United States. (pharmexec.com; usnews.com) Novo’s next scheduled update is May 6, 2026, when it reports first-quarter results. That report will show whether consumer-style fixes in pricing, channels and marketing are doing more for Wegovy than another boardroom reshuffle. (novonordisk.com)